Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease Therapy
Scientists at St. Vincent's Institute detail research in Alzheimer disease therapy
April 10th, 2007
New research, "Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions," is the subject of a report. According to a study from Fitzroy, Australia, "Alzheimer's disease (AD) is the major cause of dementia. Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the amyloid precursor protein (APP), is central to AD pathogenesis." "APP can function as a metalloprotein and modulate copper (Cu) transport, presumably via its extracellular Cu-binding domain (CuBD). Cu binding to the CuBD reduces Abeta levels, suggesting that a Cu mimetic may have therapeutic potential. We describe here the atomic...
Source: Drug Law Weekly (2007-04-10)
|
